fingolimod mylan
mylan ireland limited - финголимод хидрохлорид - Множествена Склероза, Рецидивно-Ремиттирующее - Имуносупресори - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 и 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
fixaprost 50 micrograms/ml + 5 mg/ml eye drops, solution in single-dose container
50 micrograms/ml + 5 mg/ml eye drops, solution in single-dose container
netilmicin/dexamethasone newline pharma 3 mg/ml + 1 mg/ml eye drops, solution in single-dose container
3 mg/ml + 1 mg/ml eye drops, solution in single-dose container
taflotan 15 micrograms/ml eye drops, solution in single - dose container
santen oy - 15 micrograms/ml eye drops, solution in single - dose container
dexafree 1 mg/ml eye drops, solution in single - dose container
laboratoires thea - Дексаметазон - 1 mg/ml eye drops, solution in single - dose container
softacort 3,35 mg/ml eye drops, solution in single - dose container
3,35 mg/ml eye drops, solution in single - dose container
coryzalia oral solution in single - dose container
oral solution in single - dose container
nettacin 3 mg/ml eye drops, solution in single - dose container
3 mg/ml eye drops, solution in single - dose container
elymbus 0,1 mg/g eye gel in single - dose container
0,1 mg/g eye gel in single - dose container
jyseleca
gilead sciences ireland uc, galapagos nv - filgotinib maleate - Артрит, ревматоиден - Имуносупресори - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.